196 results on '"Tsakiridis, Theodoros"'
Search Results
2. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
3. GDF15 promotes weight loss by enhancing energy expenditure in muscle
4. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
5. Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial
6. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.
7. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.
8. The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments
9. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected Locally Advanced Non-Small Cell Lung Cancer treated with chemo- radiotherapy.
10. Meta-Analysis of STereotactic body radiothERapy in non-spine BONE metastaseS (MASTER-BONES).
11. Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
12. Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers
13. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
14. 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres
15. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
16. The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada
17. Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers.
18. A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer
19. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
20. The impact of staging FDG-PET/ CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada.
21. Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.
22. Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.
23. Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.
24. Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer
25. 68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer
26. Metformin-induced reductions in tumor growth involves modulation of the gut microbiome
27. AMPK β1 reduces tumor progression and improves survival in p53 null mice
28. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial
29. Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada.
30. Salvage radiotherapy following HiFU : An institutional series and literature review
31. Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply
32. Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC)
33. NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)
34. Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
35. 18: PSMA-PET-Based Response Assessment of Metastatic Prostate Cancer Response to Radiotherapy: A Case Series
36. 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017
37. 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer
38. Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
39. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer
40. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer
41. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)
42. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
43. 194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?
44. Overall and chemotherapy‐free survival following stereotactic body radiation therapy for abdominopelvic oligometastases
45. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic
46. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel
47. Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography
48. 18F-DCFPyL (PSMA) PET as a Radiotherapy Response Assessment Tool in Metastatic Prostate Cancer.
49. 167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy
50. 40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.